Loading…
← CockpitCompetitor Analysis › 0013.HK HUTCHMED (China) LimitedOpen in the cockpit ↗

HUTCHMED (China) Limited0013.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Oncology biotech developing and commercializing targeted cancer therapies globally, including fruquintinib (Fruzaqla).

≈ A Chinese Exelixis-style oncology drug developer with global licensing dealsMomentum leader 87
Mkt cap
$2.38B
US dollars, full cap
Free float
61%
of shares outstanding
$/day
$13.3M
20-day average traded
Fwd P/E
35.9×
forward earnings
ROIC−WACC
n/a
WACC 10.7%
Hurdle
+28 pp
Req g minus delivered
Next earnings
106 days
4 Mar 2027
Close · HKDHK$21.70
1D-4.0%
1W-9.1%
1M-6.5%
3M+11.7%
6M+14.2%
YTD+5.2%
1Y-8.8%
ATR %4.4%
52w lowhigh15.2% off high

What HUTCHMED (China) does

Oncology biotech developing and commercializing targeted cancer therapies globally, including fruquintinib (Fruzaqla).

Does not sell Fruzaqla itself outside China: Takeda holds those rights, so HUTCHMED earns upfront and milestone payments, supply revenue and royalties on Takeda's sales. In China it sells some of its own drugs, and AstraZeneca pays royalties on savolitinib sales there.

In one line: A Chinese Exelixis-style oncology drug developer with global licensing deals.

Products and services

  • Fruquintinib / Fruzaqla (colorectal cancer)
  • Savolitinib (lung cancer, with AstraZeneca)
  • Oncology pipeline

Customers

  • Hospitals/oncologists in China, US, EU
  • Takeda (global licensing partner)
  • AstraZeneca (co-development partner)

Where it sits in the supply chain

  • Biotechnology
  • Oncology small-molecule drugs
  • Global licensing & commercialization

What could go right

  • Fruzaqla global sales ramp via Takeda
  • New drug approvals

What could go wrong

  • Clinical trial risk
  • Dependence on partner commercialization

Moat: narrow (IP / patents, regulatory licence). FDA/EMA-approved oncology drug with patent protection and global partner distribution.

Headquarters: Hong Kong / Shanghai, China · Founded: 2000 · Employees: 1,796

Named competitors

HUTCHMED (China) at a glance

Size HUTCHMED (China) (0013.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $2.38B, the 375th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$21.70 on 18 Nov 2026.

Performance Over six months the shares gained 14.2%, against -11.5% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue fell 8.6% over the last twelve months (peer median +5.1%); the operating margin is -6.3% (peer median 10.6%).

Valuation It trades at 35.9× forward earnings against a peer median of 26.2× (6th most expensive of 15).

Price implies For today's price to make sense, revenue must grow about 47% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is +28 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 20260013.HK 115Peer median 89
Six months, rebased to 100: HUTCHMED (China) against the median of its 20 peers (local-currency closes).

HUTCHMED (China) financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$4.29BHK$4.28BHK$4.92BHK$6.56BHK$3.34B
Revenue growth—-13%-25%+96%—
Gross profitHK$1.78BHK$1.65BHK$2.20BHK$3.55BHK$903M
EBITDA-HK$160M-HK$252M-HK$255MHK$200M-HK$3.16B
Net incomeHK$140MHK$3.56BHK$294MHK$789M-HK$2.83B
Free cash flowHK$77.2M-HK$614M-HK$136MHK$1.46B-HK$2.39B
Capital expenditureHK$82.2MHK$188MHK$140MHK$255MHK$287M
Total debtn/aHK$762MHK$698MHK$673MHK$211M

Quarterly statements and history in the cockpit →

HUTCHMED (China) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%NAMS21623696PBH000250PRGORGC301080ALM301301603858IDYAAPLLTD600867600267BIOA-B3001992144500013.HK6-month return →1-month return →
Up and to the right = strong over both horizons. HUTCHMED (China) is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%+150%25×50×75×21623696PBHPRGO301080ALM301301600267BIOA-B3001992144503005580013.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. HUTCHMED (China) is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%+100%0%50%100%3696PBHPRGO301080ALM603858APLLTD600867600267BIOA-B3001992144503005580013.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. HUTCHMED (China) is the large dot.

HUTCHMED (China) competitors and peer comparison

Head to head with its named competitors (0013.HK vs EXEL vs 1877.HK vs 1801.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
HUTCHMED (China) 0013.HK$2.38B+14%-9%-6%35.9×47.0%
Exelixis EXEL$16.7B+37%+9%40%17.7×-3.8%
Shanghai Junshi Biosciences 1877.HK$3.49B-38%+36%-14%n/an/a
Innovent Biologics 1801.HK$18.9B+4%+43%17%52.3×11.6%

How HUTCHMED (China) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

HUTCHMED (China) against its 20 peers (data as of 18 Nov 2026)
Measure0013.HKPeer medianRank in peer set
1-month return-6.5%-3.1%10th lowest of 21
6-month return+14.2%-11.5%4th highest of 21
Distance from 52-week high-15.2%-33.4%3rd highest of 21
Revenue growth (TTM)-8.6%+5.1%5th lowest of 20
Operating margin-6.3%10.6%6th lowest of 19
Forward P/E35.9×26.2×6th most expensive of 15
Growth the price implies (Req g, 7 yrs)47.0%10.1%most demanding of 15
Growth delivered (Del g)+19.3%+6.3%5th highest of 15
Hurdle (Req g minus delivered)+27.7 pp+1.9 pp2nd most demanding of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
HUTCHMED (China) 0013.HKHong Kong$2.38B+14%-9%-6%35.9×47.0%+19.3%
NewAmsterdam Pharma NAMSUnited States$2.37B-45%-26%-900%n/an/an/a
Keymed Biosciences 2162.HKHong Kong$2.39B+7%0%-73%18.2×n/an/a
InSilico Medicine Cayman TopCo 3696.HKHong Kong$2.40B-33%+153%-7%85.2×37.9%+22.9%
Prestige Consumer Healthcare PBHUnited States$2.40B+7%+5%25%10.6×2.3%+2.9%
Sam Chun Dang Pharm 000250.KSSouth Korea$2.36B-66%+23%7%n/an/an/a
Perrigo PRGOUnited States$2.35B+52%-4%5%6.7×14.1%+0.8%
Regencell Bioscience RGCUnited States$2.33B-83%n/an/an/an/an/a
Acrobiosystems 301080.SZChina$2.31B+65%+29%17%55.2×41.3%+27.7%
Almirall ALM.MCSpain$2.46B-13%+24%8%27.1×6.1%+6.5%
Yili Chuanning Biotechnology 301301.SZChina$2.49B-24%-14%16%27.6×3.4%+4.8%
Shandong Buchang Pharmaceuticals 603858.SSChina$2.25B-7%+4%10%n/a-2.5%-5.8%
IDEAYA Biosciences IDYAUnited States$2.56B-11%-83%-1,267%n/an/an/a
Alembic Pharmaceuticals APLLTD.NSIndia$2.20B+39%+20%12%25.0×26.7%+6.5%
Tonghua Dongbao Pharmaceutical 600867.SSChina$2.19B-12%+18%n/a25.4×0.9%+0.3%
Zhejiang Hisun Pharmaceutical 600267.SSChina$2.19B+14%-7%15%15.0×-9.7%-1.5%
Kangmei Pharmaceutical 600518.SSChina$2.61B-21%-6%-7%n/an/an/a
BioArctic BIOA-B.STSweden$2.66B-9%-46%22%52.9×25.5%+100.1%
Hybio Pharmaceutical 300199.SZChina$2.68B-8%+70%31%44.7×37.4%+6.1%
PharmaResearch 214450.KSSouth Korea$2.10B-24%+29%37%15.4×-11.0%+37.6%
Betta Pharmaceuticals 300558.SZChina$2.70B-15%+16%11%38.0×23.2%+14.0%

Questions

Who are HUTCHMED (China)'s main competitors?
Named competitors: Exelixis (EXEL), BeiGene (private or unlisted), Junshi Biosciences (1877.HK), Innovent Biologics (1801.HK). The cockpit's measured peer set (industry) also includes NewAmsterdam Pharma (NAMS), Keymed Biosciences (2162.HK), InSilico Medicine Cayman TopCo (3696.HK), Prestige Consumer Healthcare (PBH), Sam Chun Dang Pharm (000250.KS), Perrigo (PRGO).
Is HUTCHMED (China) expensive compared with its peers?
On forward p/e it trades at 35.9× against a peer median of 26.2×, 6th most expensive of 15 in its peer set. For today's price to make sense, revenue must grow about 47% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is +28 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has HUTCHMED (China) stock performed?
Over six months to 18 Nov 2026 the shares returned +14.2% against -11.5% for the median peer; over one year -8.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.